Pankaj Bhargava, MD, VP, Gilead Sciences

It is our pleasure to announce Bhargava, MD, VP, Oncology TA Head, Gilead Sciences with the AAPM Excellence in Transformative Therapy Award in regards to the development of CART immunotherapy -Yescarta™, which is at the forefront of precision medicine for the treatment of lymphoid cancers. Dr. Bhargava also currently serves as a faculty at UCSF, and was previously a faculty member at Harvard Medical School and Attending Physician at Dana-Farber Cancer Institute in Boston. Please join me in congratulating Dr. Bhargava, Kite Pharma (a Gilead subsidiary), and Gilead Sciences on this wonderful recognition.